Amarin Corporation Plc

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amarin reports robust Q4 earnings, eyes global expansion opportunities

Amarin's Q4 2022 earnings call highlighted strong financial performance, successful global expansion efforts, and a focus on cash preservation and talent acquisition. The company's UK launch milestones and international progress position it well for future growth.

Amarin reports Q1 revenue growth amidst pricing challenges and opportunities

Amarin focuses on revenue growth and cost-saving initiatives to drive operational efficiency and profitability.
The company's strong cash position provides stability for future growth initiatives and strategic investments.
Challenges include pricing pressure from generics and the need to balance expenses with revenue growth.
Opportunities lie in expanding prescription growth, product portfolio, and exploring strategic partnerships.

Amarin Corporation Plc reports robust Q3 earnings and strategic growth plans

Amarin Corporation Plc's Q3 2023 earnings call showcased strong financial performance, operational decisions driving positive cash flow, and a focus on maximizing shareholder value. While challenges in the European market and uncertainties around stock price were noted, opportunities for growth in global markets and strategic initiatives offer potential for future success.

Amarin reports solid Q4 revenue growth and eyes global expansion

Amarin's Q4 2023 performance reflects revenue growth and ongoing investment in strategic initiatives.
The company's strong financial position and operational momentum in key markets position it well for future growth.
Challenges around market dynamics, expenses management, and competition require strategic focus for sustained success.

Amarin reports stable Q1 earnings, focuses on European growth opportunities

Amarin Corporation's Q1 2024 earnings call highlighted solid financial performance, successful IP defense in Europe, and positive clinical outcomes for its key products. While facing challenges in the U.S. market due to generic competition, the company maintains profitability and a strong cash position. Opportunities lie in shareholder value enhancement and continued growth in Europe.

Amarin reports stable revenue but faces generic competition challenges

Amarin's Q2 2024 performance reflects revenue decline in the U.S. due to generic competition but improved net income from expense reductions. The company's strengths lie in the success of Vascepa/VAZKEPA and maintaining market share. Challenges include adapting to changing market dynamics, while opportunities exist in global expansion and strategic initiatives.

Amarin reports Q3 revenue of $42.3M, focuses on global expansion

Amarin's Q3 2024 performance reflects a mixed financial outcome with total net revenue of $42.3M and a GAAP net loss of $25.1M, impacted by challenges in the U.S. generic market.
Despite facing pricing pressures and cost reduction efforts, the company maintains a stable cash position of $306M and remains focused on global expansion.
The strengths lie in the proven science and support for VASCEPA/VAZKEPA, with opportunities to address the unmet need in reducing cardiovascular disease globally.
Challenges include navigating market dynamics and maintaining profitability amidst pricing pressures, while upcoming events signal proactive engagement for long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Company Received Final Positive Reimbursement Decision for VAZKEPA® by UK's NICE in England & Wales

Amarin Reports Second Quarter 2022 Financial Results and Provides Business Update

DUBLIN, Ireland and BRIDGEWATER, N.J., July 20, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin's senior management team to discuss the Company's second quarter 2022 financial results on Wednesday, August 3rd, 2022 at 8:00 a.m. ET.

Amarin to Report Second Quarter 2022 Financial Results and Host Conference Call on August 3, 2022

The drugmaker's downward spiral continued.

Why Amarin Stock Dipped This Week

-- Newly published final guidance by the National Institute for Health and Care Excellence (NICE) in the UK confirms its prior draft recommendation for the use of VAZKEPA® (icosapent ethyl) in England and Wales to reduce the risk of cardiovascular (CV) events in adult statin-treated patients at high CV risk who have elevated triglycerides (≥150 mg/dL [≥ 1.7 mmol/L]), controlled LDL-C between 1.04 mmol/L - 2.60 mmol/L and established cardiovascular disease (eCVD). 1 , 2 -- DUBLIN, Ireland and BRIDGEWATER, N.J., July 13, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that NICE has issued its final guidance recommending VAZKEPA® (icosapent ethyl) for reimbursement and use across the National Health Service (NHS) in England and Wales to help reduce the risk of major CV events in high-risk statin-treated patients with eCVD, at a price of £144.21 per 120 soft capsules (i.e. 30 day supply; the equivalent of approximately 171 EUR or 172 USD*).

NICE Issues Final Guidance for Reimbursement Making VAZKEPA® (icosapent ethyl) Available Across the NHS in England & Wales

DigitalBridge Group

Evofem Biosciences Inc

What you need to know about trading penny stocks this month The post July Penny Stocks Buying Guide, 3 Things to Know appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

July Penny Stocks Buying Guide, 3 Things to Know

-- Sub-Analysis Findings Support Prior Analyses that Eicosapentaenoic Acid (EPA) Level is  The Major Determinant of Benefit in REDUCE-IT -- DUBLIN, Ireland and BRIDGEWATER, N.J., June 30, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced an exploratory post hoc sub-analysis of REDUCE-IT serum samples that found statin-treated patients allocated to icosapent ethyl (IPE) had limited differences in certain lipid and inflammatory biomarkers compared with statin-treated patients allocated to mineral oil placebo. These findings are consistent with prior reported data and support previous analyses that demonstrated the majority of benefit from IPE was from achieved eicosapentaenoic acid (EPA) levels in REDUCE-IT. This sub-analysis was published online today in the journal Circulation.

REDUCE-IT Exploratory Post Hoc Biomarker Sub-Analysis Shows Relatively Small Changes in Inflammatory Markers Between Icosapent Ethyl and Placebo

GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital Management LP (“Sarissa”) today made the following statement on Amarin Corporation plc (NASDAQ: AMRN) regarding how it intends to vote at the upcoming Amarin annual meeting and the reasons therefor: Sarissa is a sophisticated, institutional investor with a long history of shareholder value creation in healthcare companies, including in the cardiovascular space, such as The Medicines Company. As Amarin's largest shareholder, we are frustrated by

Sarissa Capital Intends to Vote “Abstain” at the Amarin Annual Meeting

UK's NICE issued its draft Final Appraisal Document (FAD) recommending the use of VAZKEPA® (icosapent ethyl) in England and Wales to reduce the risk of cardiovascular (CV) events in adult statin-treated patients at high CV risk who have elevated triglycerides (≥150 mg/dL [≥ 1.7 mmol/L]) and established cardiovascular disease (eCVD)  1 , 2

Amarin Receives Positive Recommendation from United Kingdom's (UK) National Institute for Health and Care Excellence (NICE) for Reimbursement of VAZKEPA® (icosapent ethyl)

Amarin Corporation plc 2022 Jefferies Global Healthcare Conference Call June 8, 2022 1:00 PM ET Company Participants Karim Mikhail - President and Chief Executive Officer Conference Call Participants Michael Yee - Jefferies Michael Yee Thank you. Well, good afternoon, everyone, and thank you for joining us at another great session here at the 2022 Jefferies In-Person Healthcare Conference.

Amarin Corporation plc's (AMRN) CEO Karim Mikhail on 2022 Jefferies Global Healthcare Conference (Transcript)

Clovis Oncology

Mullen Automotive

Quoin Pharmaceuticals Ltd

Penny stocks to watch The post Penny Stocks To Buy Now? 4 To Watch With Big News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy Now? 4 To Watch With Big News

Shares of Amarin Corp. AMRN, hiked up 5.4% in premarket trading Monday, after the drug maker said it would reduce its workforce by 40% as part of its plan to cut operating costs by $100 million over the next 12 months.

Amarin stock surges after plan to cut total workforce by 40%

-- Company Expects to Achieve Approximately $100 Million in Cost Savings Over the Next 12 Months* While Continuing to Invest in European Launches and Global Expansion -- -- Reduces U.S. Commercial Organization by Ninety Percent of Pre-Pandemic / Pre-Generic Competition Levels --

Amarin Announces Comprehensive Cost Reduction Plan to Address Market Dynamics in U.S. Business

-- Experienced Executive Brings More Than Twenty Years of Global Financial Leadership to Amarin -- -- Michael W. Kalb to Depart Amarin to Pursue Other Interests --

Amarin Appoints Tom Reilly as New Chief Financial Officer

An activist investor is getting more active with the company.

Why Amarin Stock Blasted Higher on Friday

Applied Therapeutics Inc

Society Pass

Exela Technologies

Hot penny stocks to watch. The post 4 Hot Penny Stocks With News To Watch Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Hot Penny Stocks With News To Watch Right Now

The biopharmaceutical company's lowered revenue is scaring off investors.

Why Shares of Amarin Corporation Dropped 46.1% in May

Amarin Corporation plc (NASDAQ:AMRN ) H.C. Wainwright Global Investment Conference Call May 25, 2022 12:00 PM ET Company Participants Karim Mikhail - President & Chief Executive Officer Conference Call Participants Matthew Caufield - H.C.

Amarin Corporation Plc (AMRN) CEO Karim Mikhail on H.C. Wainwright Global Investment Conference (Transcript)

Erin Enright and Alfonso “Chito” Zulueta Appointed to Board of Directors

Amarin Announces Appointment of New Directors and Board Leadership Changes

DUBLIN, Ireland and BRIDGEWATER, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that research on the potential population health impact and cost-effectiveness of VASCEPA® (icosapent ethyl), presented in two poster presentations at the American Heart Association's Quality of Care and Outcomes Research Scientific Sessions in Reston, VA, May 13-14, 2022, showcased significant potential to reduce major cardiovascular (CV) events and associated costs.

Research Presented at the American Heart Association's Quality of Care and Outcomes Research (QCOR) Scientific Sessions Indicate Potential for VASCEPA® (icosapent ethyl) to Reduce Major Adverse Cardiovascular (CV) Events and Associated Costs

New York, New York--(Newsfile Corp. - May 9, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Amarin Corporation plc ("Amarin" or the "Company") (NASDAQ: AMRN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Amarin and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Amarin Corporation plc - AMRN

Amarin's (AMRN) Vascepa sales decline year over year amid rising generic competition and COVID-related disruptions during the first quarter. The company's stock falls significantly on May 4.

Amarin (AMRN) Q1 Earnings & Sales Hurt by Vascepa Generics

Amarin Corporation plc (NASDAQ:AMRN ) Q1 2022 Earnings Conference Call May 4, 2022 8:00 AM ET Company Participants Lisa DeFrancesco - Senior Vice President, Investor Relations and Corporate Affairs Karim Mikhail - President and Chief Executive Officer Steve Ketchum - President, R&D and Chief Scientific Officer Mike Kalb - Chief Financial Officer Conference Call Participants Louise Chen - Cantor Roanna Ruiz - SVB Securities Jessica Fye - JPMorgan Paul Choi - Goldman Sachs Operator Welcome to Amarin Corporation's Conference Call to discuss its First Quarter 2022 Financial Results and Operational Updates. This conference call is being recorded today, May 4, 2022.

Amarin Corporation plc (AMRN) CEO Karim Mikhail on Q1 2022 Results - Earnings Call Transcript

Missed expectations on the top and bottom lines suggest Amarin's path forward isn't as clear as investors want it to be.

Why Amarin Stock Is Sinking on Wednesday

Amarin Corporation plc (NASDAQ: AMRN) shares are plunging after it said it would continue suspending 2022 revenue guidance and Q1 earnings came short of expectations. The update follows the ongoing global impact of COVID-19 and the uncertainty resulting from the impact of generic icosapent.

Why Amarin Shares Are Plunging After Q1 Earnings

Initiated Next Phase of European Expansion Strategy with First National Reimbursement in Sweden

News for Amarin Corporation Plc Stock (AMRN)